Navigation Links
Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
Date:12/9/2008

gnosed AML, between 60 and 76 years of age. A second Phase 2 study of CPX-351 in patients 18-60 years old with AML in first relapse is also being initiated.

About Acute Myeloid Leukemia (AML)

The National Cancer Institute defines AML as a quickly progressing disease in which too many immature white blood cells (not lymphocytes) are found in the blood and bone marrow. In 2008, the American Cancer Society's Cancer Facts and Figures estimates 13,290 new cases of AML and 8,820 deaths.

About Celator

Celator(R) Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, locks the desired ratio in a drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com.

List of abstracts:

ASH Abstract # 942

Mayer L, Wahseng L, Dos Santos N, et al. Synergistic cytarabine:daunorubicin ratios
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
2. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
3. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
4. Savient Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference on January 14th
5. ISTA Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference
6. Middlebrook Pharmaceuticals Opens Administrative and Sales Office in Westlake, Texas
7. Memory Pharmaceuticals Receives NASDAQ Decisions
8. MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference
9. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
10. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
11. Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... August 21, 2014 The new ... from Lockton Companies and builds on Accountable Health ... cellular glucometer, combined with Accountable Health’s robust member ... analytic capabilities and adds a custom incentive platform ... eye exams, provider visits, HbA1c testing and more. ...
(Date:8/21/2014)... 21, 2014 Relias Learning, the leader ... and human services markets, announced the latest release of ... the Tin Can API. , “Supporting the Tin ... the most advanced mobile learning capabilities and the ability ... tools and techniques,” says Jim Triandiflou, CEO of Relias ...
(Date:8/21/2014)... to be elicited by T-type calcium channels in ... regulate influxes of calcium. These channels enable thalamic ... the neurons to enter a hyper-excited state. , ... firing and absence seizures, the researchers conducted an ... gene targeting techniques to delete the T-type calcium ...
(Date:8/21/2014)... August 21, 2014 ... Peripheral Vascular Devices Market by Angioplasty ... Catheter (IVUS, OCT), IVC Filter (Retrievable), ... 2018" analyzes and studies the major ... the U.S. and Canada. , Browse ...
(Date:8/21/2014)... mynt welcomes industry leaders Rob and ... its growing company. Since its pre-launch in April, mynt ... and continues to gain momentum leading up to its ... Tiffanie came into network marketing by chance. Tiffanie worked ... network marketing companies. Tiffanie needed help at one particular ...
Breaking Medicine News(10 mins):Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 2Health News:Accountable Health Expands Diabetes Management Solutions to Address Gaps in Provider Care 3Health News:Relias Learning Announces Support for Tin Can API 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 2Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 3Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 4Health News:North American Interventional Cardiology and Peripheral Vascular Devices Market worth $5.9 Billion by 2018 - Research Report by MarketsandMarkets 5Health News:Industry Leaders Rob and Tiffanie Moffitt Join mynt 2
... for cancer when they were children have a higher-than-average ... severe in the years following treatment, according to ... of the International Society of Paediatric Oncology (SIOP) in ... Cancer Center and their colleagues say their findings suggest ...
... scientists will receive grants totaling $9.35 million to help ... and traumatic brain injury. The grants from the ... 21, to Dr. Henry Klassen, Leslie M. Thompson, Brian ... Sue and Bill Gross Stem Cell Research Center at ...
... cholesterol-lowering drug reduced the enlarged prostates of hamsters to the ... prostatic hyperplasia (BPH), report researchers at Children,s Hospital Boston and ... Urology. Together, the drugs worked even better. "We don,t ... lowering cholesterol has the potential to reduce BPH in men," ...
... WHAT: Researchers funded by the National Institutes of Health have ... is evolving into two separate species with different traits, ... and potentially require new disease prevention methods. Their findings ... issue of the journal Science . A. ...
... of California, San Diego School of Medicine indicates that parent-only ... that include parents and child, while at the same time ... The results were published today in the advanced online edition ... PhD, associate professor of pediatrics and psychiatry at UC San ...
... -- If you,re a nonsmoker who lives in an apartment, ... smoke, says a new study. Researchers at Roswell Park ... 30 apartments within 11 buildings and found that secondhand smoke ... apartments of nonsmokers. The extent of the secondhand smoke ...
Cached Medicine News:Health News:Childhood cancer survivors face long-term risk of GI complications, study finds 2Health News:UCI stem cell researchers to receive $9.35 million in state funding 2Health News:UCI stem cell researchers to receive $9.35 million in state funding 3Health News:Cholesterol-lowering drug shrinks enlarged prostates in hamster model 2Health News:Parent-only treatment may be equally effective for children who are obese 2
(Date:8/21/2014)... Professional Compounding Centers of America (PCCA) ... the three best scientific presentations at the sixth ... The Formulating Better Medicines for Children  conference, ... Athens, Greece , includes dozens of poster-style ... which three winners will be selected by a ...
(Date:8/21/2014)... 2014   Royal Philips (NYSE: ... has received 510(k) clearance from the U.S. Food ... application for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through ... with pre-procedural, high-precision positioning to treat aortic stenosis ... is available as part of Philips IntelliSpace ...
(Date:8/21/2014)... 21, 2014  SI-BONE, Inc. ( San Jose, ... the use of the iFuse Implant System, ® ... of the sacroiliac (SI) joint, announced that Priority Health ... its Lumbar Fusion Medical Policy No. 91590-R4 providing positive ... policy states that the fusion procedure, which employs the ...
Breaking Medicine Technology:Professional Compounding Centers of America will award top poster-session winners at European Paediatric Formulation Initiative in Athens 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: